1 **Comparative genomics and antimicrobial resistance profiling of *Elizabethkingia* isolates**
2 **reveals nosocomial transmission and *in vitro* susceptibility to fluoroquinolones,**
3 **tetracyclines and trimethoprim-sulfamethoxazole**

4

5 Delaney Burnard^{1,3,4#}, Letitia Gore^{2#}, Andrew Henderson¹, Ama Ranasinghe¹, Haakon
6 Bergh², Kyra Cottrell¹, Derek S. Sarovich^{3,4}, Erin P. Price^{3,4}, David L. Paterson¹, Patrick N.
7 A. Harris^{1,2*}

8 ¹University of Queensland Centre for Clinical Research, Royal Brisbane and Woman's
9 Hospital, Herston, Queensland, Australia

10 ²Central Microbiology, Pathology Queensland, Herston, Queensland, Australia

11 ³Genecology Research Centre, University of the Sunshine Coast, Sippy Downs, Queensland,
12 Australia

13 ⁴Sunshine Coast Health Institute, Birtinya, Queensland, Australia

14 [#]Authors contributed equally

15 ***Corresponding author:** Dr Patrick N. A. Harris

16 University of Queensland Centre for Clinical Research, Building 71/918 Royal Brisbane &
17 Women's Hospital Campus, Herston, QLD, 4029

18 **Email:** p.harris@uq.edu.au; **Tel:** +61 (0) 7 3346 6081

19 Word count abstract:436, Word count text:4,493

20 **Keywords:** *Elizabethkingia*, MDR, multidrug resistance, nosocomial, MIC, minimum
21 inhibitory concentration, antimicrobial resistance, AMR, comparative genomics

22 Abstract

23 The *Elizabethkingia* genus has gained global attention in recent years as a nosocomial
 24 pathogen. *Elizabethkingia* spp. are intrinsically multidrug resistant, primarily infect
 25 immunocompromised individuals, and are associated with high mortality (~20-40%).
 26 Although *Elizabethkingia* infections appear sporadically worldwide, gaps remain in our
 27 understanding of transmission, global strain relatedness and patterns of antimicrobial
 28 resistance. To address these knowledge gaps, 22 clinical isolates collected in Queensland,
 29 Australia, over a 16-year period along with six hospital environmental isolates were
 30 examined using MALDI-TOF MS (VITEK[®] MS) and whole-genome sequencing to compare
 31 with a global strain dataset. Phylogenomic reconstruction against all publicly available
 32 genomes ($n=100$) robustly identified 22 *E. anophelis*, three *E. miricola*, two *E.*
 33 *meningoseptica* and one *E. bruuniana* from our isolates, most with previously undescribed
 34 diversity. Global relationships show Australian *E. anophelis* isolates are genetically related to
 35 those from the USA, England and Asia, suggesting shared ancestry. Genomic examination of
 36 clinical and environmental strains identified evidence of nosocomial transmission in patients
 37 admitted several months apart, indicating probable infection from a hospital reservoir.
 38 Furthermore, broth microdilution of the 22 clinical *Elizabethkingia* spp. isolates against 39
 39 antimicrobials revealed almost ubiquitous resistance to aminoglycosides, carbapenems,
 40 cephalosporins and penicillins, but susceptibility to minocycline, levofloxacin and
 41 trimethoprim/sulfamethoxazole. Our study demonstrates important new insights into the
 42 genetic diversity, environmental persistence and transmission of Australian *Elizabethkingia*
 43 species. Furthermore, we show that Australian isolates are highly likely to be susceptible to
 44 minocycline, levofloxacin and trimethoprim/sulfamethoxazole, suggesting that these
 45 antimicrobials may provide effective therapy for *Elizabethkingia* infections.

46 **Importance**

47 *Elizabethkingia* are a genus of environmental Gram-negative, multidrug resistant,
 48 opportunistic pathogens. Although an uncommon cause of nosocomial and community-
 49 acquired infections, *Elizabethkingia* spp. are known to infect those with underlying co-
 50 morbidities and/or immunosuppression, with high mortality rates of ~20-40%.
 51 *Elizabethkingia* have a presence in Australian hospitals and patients; however, their origin,
 52 epidemiology, and antibiotic resistance profile of these strains is poorly understood. Here, we
 53 performed phylogenomic analyses of clinical and hospital environmental Australian
 54 *Elizabethkingia* spp., to understand transmission and global relationships. Next, we
 55 performed extensive minimum inhibitory concentration testing to determine antimicrobial
 56 susceptibility profiles. Our findings identified a highly diverse *Elizabethkingia* population in
 57 Australia, with many being genetically related to international strains. A potential
 58 transmission source was identified within the hospital environment where two transplant
 59 patients were infected and three *E. anophelis* strains formed a clonal cluster within the
 60 phylogeny. Furthermore, near ubiquitous susceptibility to tetracyclines, fluoroquinolones and
 61 trimethoprim/sulfamethoxazole was observed in clinical isolates. We provide new insights
 62 into the origins, transmission and epidemiology of *Elizabethkingia* spp., in addition to
 63 understanding their intrinsic resistance profiles and potential effective treatment options,
 64 which has implications to managing infections and detecting outbreaks globally.

65

66 Introduction

67 The genus *Elizabethkingia* (formerly *Chryseobacterium*), comprise a group of environmental
68 bacteria that have traditionally been isolated from soil and water environments¹⁻⁴. As
69 opportunistic pathogens, *Elizabethkingia* spp. can cause sporadic nosocomial outbreaks and
70 infections in immunocompromised or at-risk individuals^{1,2,5-8}. Infections have been
71 documented worldwide such as those in the Central African Republic⁹, Mauritius¹⁰,
72 Singapore¹¹, Taiwan¹² and the USA⁶, suggesting a comprehensive global distribution that is
73 yet to be fully described. Often, the source of *Elizabethkingia* spp. infection remains unclear
74 and routes of transmission are still to be defined^{2,6,9,12-16}. However, previous investigations
75 have suggested that shared water reservoirs within hospitals may be an overlooked source of
76 infection^{1,2,17}.

77

78 As an understudied pathogen, taxonomic assignment within the *Elizabethkingia* genus is
79 ongoing. Recently, a formal taxonomic revision using whole-genome sequencing (WGS) left
80 the previously described species *E. meningoseptica* and *E. miricola* unchanged, while the
81 proposed species *E. endophytica*¹⁸ is now considered a clone within *E. anophelis*¹⁹⁻²¹. Several
82 new species, *E. bruuniana*, *E. ursingii*, and *E. occulta* have recently been described³⁻⁵. It is
83 also now recognised that *E. anophelis*, not *E. meningoseptica*, is the primary species causing
84 human infection, although clinical presentations may be very similar^{4,13,22-24}. The remaining
85 members of the genus are thought to be much less prevalent in human disease; however,
86 difficulties in accurately identifying *E. miricola*, *E. bruuniana*, *E. ursingii*, and *E. occulta*
87 from clinical specimens has hindered appropriate recognition and characterisation of these
88 species⁴.

89

Common clinical presentations of *E. anophelis* infections include primary bacteraemia, pneumonia, sepsis and meningitis in neonates^{7,14,22,23}. Risk factors associated with *E. anophelis* infection consist of being male, having underlying chronic medical conditions such as malignancy or diabetes mellitus, and admission to critical care or neonatal units^{13,22,23,25}. Currently, approximately 80% of *E. anophelis* infections are considered hospital-acquired with mortality rates ranging from 23-26%^{22,23,25}. Similarly, *E. meningoseptica* infections also present as neonatal meningitis and/or sepsis but can also cause infections in most organ systems. Primary bacteraemia is the most common presentation, occurring more often in hospitalised patients and those with underlying co-morbidities^{8,12}. The mortality rate of *E. meningoseptica* infection is between 23-41%, with higher rates in individuals where premature birth, shock or admission to a critical care unit has taken place^{12,26}. To date, the largest outbreak was caused by community-acquired *E. anophelis* in Wisconsin, USA, from 2015-2016. A total of 66 individuals were infected and the outbreak spread to the neighbouring states of Illinois and Michigan⁶. Comparative genomics characterised unique mutations in an integrative conjugative element (ICE) insertion in the *MutY* gene in all infecting strains as well as a mutation in the *MutS* gene in hypermutator strains, which may have accelerated the transmission of the outbreak clone⁶.

107

Poorly understood intrinsic multidrug resistance (MDR) in *E. anophelis* and *E. meningoseptica* infections has led to inappropriate empiric antibiotic therapy, especially in patients with underlying co-morbidities, in critical care^{12,26} or neonatal units^{1,2,8,13,15,16,27}, resulting in high mortality rates. There are currently no established minimum inhibitory concentration (MIC) breakpoints for *Elizabethkingia* spp., causing reported susceptibility rates to vary among studies. Despite interpretation differences, *Elizabethkingia* are generally considered resistant to carbapenems, cephalosporins, aminoglycosides, and most β -lactams

even in combination with β -lactamase inhibitors (except for piperacillin/tazobactam). Minocycline, levofloxacin, trimethoprim/sulfamethoxazole and piperacillin/tazobactam are the most common antimicrobials that have been tested and generally demonstrate widespread susceptibility^{4,6,23–25,28}. Interestingly, *in vitro* susceptibility to the Gram-positive glycopeptide vancomycin has been documented in *Elizabethkingia* spp., resulting in vancomycin being suggested as a therapy^{4,29–31}. Based on these results the empiric antibacterial therapy of choice for *Elizabethkingia* spp. infections is not clear, but should ideally be guided by further MIC profiling^{7,23,25,31}.

Here, we present one of the largest comparative genomic analyses of the *Elizabethkingia* genus to date, which includes 22 newly described clinical isolates and six hospital environmental isolates from Australia, a previously underrepresented geographic area. The speciation accuracy of the VITEK[®] MS v3.2 database was assessed, in addition to a comprehensive examination of clinical isolates using both genomic data and MIC testing across 39 antimicrobials. Our results provide valuable insights into global *Elizabethkingia* relationships, speciation accuracy, transmission, the extent of intrinsic antimicrobial resistance and options for potential effective antimicrobial therapy to combat these opportunistic pathogens.

Methods

Ethics statement

This project was reviewed by the chairperson of a National Health and Medical Research Council (NHMRC) and registered with The Royal Brisbane and Women's Hospital Human Research Ethics Committee (HREC) (EC00172) and was deemed compliant with the NHMRC guidance "Ethical considerations in Quality Assurance and Evaluation Activities" 2014 and exempt from HREC review.

Isolates and initial identification

Twenty-two clinical *Elizabethkingia* spp. isolates collected in Queensland, Australia over a 16-year period (2002-2018) were included in this study (Table 1). Isolates were collected by two methods. First, laboratory database storage records from multiple public and private laboratories in Queensland were searched for *Elizabethkingia* spp. or *Chryseobacterium meningoseptica*. Second, isolates identified by current laboratory identification systems as *Elizabethkingia* spp. were collected prospectively from both private and public pathology laboratories throughout the state of Queensland between January 2017 and October 2018. All isolates were stored at -80°C with low temperature bead storage systems. Single colonies were double passaged from clinical specimens on 5% horse blood agar (Edwards Group MicroMedia, Narellan, NSW, Australia) then subjected to identification via VITEK® MS Knowledge Base v3.2 (bioMérieux, Murarrie, QLD, Australia) which is inclusive of *E. anophelis*, *E. miricola* and *E. meningoseptica*.

Furthermore, six environmental isolates were collected in 2019 from a participating hospital via swabbing various surfaces throughout the environment (Table 1). Specimens were plated onto 5% horse blood agar and *Elizabethkingia* spp. colonies were double passaged to ensure purity then subjected to identification via VITEK® MS Knowledge Base v3.2.

159

160 *DNA extraction, whole-genome sequencing and genome assembly*

161 DNA was extracted using the DNeasy Ultra Clean Microbial extraction kit (Qiagen,
162 Chadstone, VIC, Australia) according to the manufacturer's instructions. Purified DNA was
163 quantified using both the NanoDrop 3300 spectrophotometer and the QubitTM 4 fluorometer
164 (Thermo Fisher Scientific). Sequencing libraries were generated using the Nextera Flex DNA
165 library preparation kit and sequenced on the MiniSeqTM System (Illumina Inc.[®], San Diego,
166 CA, USA) on a high output 300 cycle cartridge according to the manufacturer's instructions.
167 Comparative genomic analyses were performed across a large *Elizabethkingia* data set
168 ($n=128$; Table S1), including the 28 Australian genomes generated in the current study (Table
169 1), to assign species and to assess intraspecific and geographical relationships among strains.
170 Publicly available *Elizabethkingia* Illumina reads ($n=119$) were downloaded from the NCBI
171 Sequence Read Archive database (January 2019), and *Elizabethkingia* spp. assemblies were
172 downloaded from the GenBank database ($n=109$). Publicly available Illumina reads were
173 quality-filtered with Trimmomatic v0.38³² and subject to quality control assessments with
174 FastQC³³, followed by downsizing using Seqtk to 40x coverage³⁴. For assemblies without
175 accompanying Illumina data, synthetic paired-end reads were generated with ART
176 MountRainier-2016.06.05³⁵. Genomes were limited to one representative per strain, and only
177 high-quality sequence reads according to FastQC were included to avoid errors in
178 phylogenomic reconstruction ($n=100$; Table S1). The genomes were assembled using SPAdes
179 v3.13.0³⁶ and annotated with Prokka v1.13³⁷ (Table S2).

180

181 *Phylogenomic reconstruction*

The comparative genomics pipeline SPANDx v3.2³⁸ was used under default settings to identify orthologous, biallelic, core-genome single-nucleotide polymorphism (SNP) and short insertion-deletion (indel) characters among the 128 *Elizabethkingia* genomes. *E. anophelis* NUHP1, *E. miricola* CSID3000517120, *E. meningoseptica* G4120 and *E. bruuniana* G0146 (GenBank accession numbers NZ_CP007547.1, NZ_MAGX000000000.1, NZ_CP016378.1 and NZ_CP014337.1 respectively) were used as reference genomes for SPANDx read mapping alignment. Outputs from SPANDx were used to generate maximum parsimony trees using PAUP version 4.0a³⁹ and visualised in FigTree v4.0 (<http://tree.bio.ed.ac.uk/software/figtree>). From the 128 genomes 127,236 SNPs and were used to construct the *Elizabethkingia* genus phylogeny (Figure 1.). Within-species phylogenies were also constructed using 121,827 SNPs from 71 genomes for *E. anophelis* (Figure 2), 135,087 SNPs from 18 genomes for *E. miricola* (Figure 3), 61,500 SNPs from 22 genomes for *E. meningoseptica* (Figure 4) and 82,680 SNPs from 10 genomes for *E. bruuniana* (Figure 5) phylogenies respectively. All phylogenies were statistically tested with 1000 bootstrap replicates. Branch support of less than 0.8 is shown in figures. To assess SNP and indel differences amongst closely related strains, the earliest collected strain was used as the reference in SPANDx, SNP and indel variants that had passed quality filtering were visualised in Tablet 1.19.09.03⁴⁰ and Geneious Prime 2019 2.1⁴¹ (Table 2).

Minimum Inhibitory Concentration (MIC) testing

Elizabethkingia spp. clinical isolates were subjected to broth microdilution to determine MICs for 39 clinically relevant antimicrobials consistent with or complementary to previous *Elizabethkingia* studies^{12,23,28,42} (Tables 3 & 4). Custom Gram-negative Sensititre MIC Plates (ThermoFisher Scientific, Scoresby, VIC, Australia) were used according to manufacturer's

instructions. *E. bruuniana* isolate, EkQ11, was excluded from MIC analyses due to poor growth. *Elizabethkingia* spp. isolates were compared against the European Committee on Antimicrobial Susceptibility Testing (EUCAST) pharmacokinetic-pharmacodynamic (PK-PD) “non-species” breakpoints⁴³ and the non-*Enterobacteriaceae* breakpoints as per the Clinical and Laboratory Standards Institute (CLSI) M45 guidelines^{44–46}.

In silico antimicrobial resistance (AMR) gene predictions

Clinical *Elizabethkingia* spp. WGS data were subject to ABRicate set to the CARD database to predict AMR genes (<https://github.com/tseemann/abricate>) and RAST for a secondary confirmation^{42,47,48}. Geneious prime 2019.2.1 and BLAST (<https://blast.ncbi.nlm.nih.gov/Blast.cgi>) were used to generate single protein sequence alignments⁴¹.

Data availability

Illumina sequence data for the 28 *Elizabethkingia* spp. genomes described in this study have been deposited in the NCBI SRA database under identifier SRP225137, BioProject PRJNA576977 (BioSample accessions: SAMN13016226-SAMN13016247 and SAMN14081590- SAMN14081595).

Results

Elizabethkingia speciation using comparative genomics vs mass spectrometry

Phylogenomic reconstruction of 100 *Elizabethkingia* reference genomes collected globally over the past 50 years and the 28 Australian clinical and environmental *Elizabethkingia* spp. genomes robustly identified as *E. anophelis* ($n=22$), *E. miricola* ($n=3$), *E. meningoseptica* ($n=2$) and *E. bruuniana* ($n=1$) (Figure 1; Table S1). Eleven speciation errors were identified in the publicly available dataset consisting of two speciation errors within the *E. anophelis* clade, five within the *E. bruuniana* clade and one within the *E. miricola* clade (Figure 1). Additionally, comparison of the VITEK[®] MS Knowledge Base v3.2 with genomic species assignments of the Australian isolates resulted in one speciation error in this study, incorrectly identifying *E. bruuniana* as *E. miricola* (Table 1).

Australian *Elizabethkingia* and global relatedness

Australian *Elizabethkingia* spp. displayed no distinct phylogeographical signal within the genus phylogeny as they disseminated across the phylogenetic tree (Figure 1.) However, multiple introduction events appear to have taken place, as at least five clades with Australian representatives are branching with international strains, for example: EkQ1, 10 & 13 branching with HvH-WGS333 and EM_CHUV from Denmark and Switzerland respectively, EkS4 branching with CSID_3015183679 from Wisconsin, environmental strains EK1,3,4,5 branching with NUH11 and 6 from Singapore, EkQ15 branching with F3201 from Kuwait and EkQ4 clustering with 61421PRCM, G4120 and UBA907 from China, France and New York, respectively (Figure 1). No Australian *Elizabethkingia* isolate was identical to a previously described isolate, with those appearing to be near identical in the phylogenies separated by 16-284 SNPs (Figures 1-5). Australian *E. anophelis* are not closely related to

Wisconsin, USA outbreak strains (Figure 1, Figure 2). Clinical isolates EkQ17, Q5, S2 and environmental isolates EK2 and EK6 branched off the Wisconsin, USA outbreak cluster, diverging as a distantly related unique lineage separated by an estimated 20,400 SNPs and 500 indels using CSID_3015183681 as the reference strain. The truncation of the C-terminal of MutY and MutS, characteristic of the outbreak and hypermutator strains were not evident in Australian strains in the amino acid alignment. The 2019 hospital environmental isolates EK1, EK3, EK4, and EK5, collected from various wards handwashing sinks or toilet environments from the same hospital as EkQ5-EkQ17-EK6-EK2, are closely related to two 2012 Singaporean isolates, NUH6 and NUH11. These isolates are separated by 656-867 SNPs and 41-72 indels, and all share a clade with 2016 outbreak isolate CSID_3015183686, which differs from the Singapore isolates by an estimated 9800 SNPs and 260 indels.

Evidence of E. anophelis nosocomial transmission

Two instances of recent closely related Australian *E. anophelis* isolates were identified on two separate lineages by phylogenetic analysis (Figure 2), both with bootstrap support of 1. In the first instance EkM1 and EkM2 were collected from the same patient one month apart, branching as unique lineage with clinical isolate EkQ6 from a patient in a different hospital. All strains were collected in 2018 and did not show evidence of within host evolution (Figure 2).

In the second instance, diverging from the Wisconsin outbreak cluster in the *E. anophelis* phylogeny are five epidemiologically linked clinical isolates EkQ5, EkQ17, EkS2 and environmental isolates EK2 and EK6 (Figure 2). SNP and indel comparisons between clinical strains EkQ5 and EkQ17 revealed a difference of eight SNPs and one indel between two different patients admitted into the same transplant ward nine months apart in 2018.

Epidemiologically, these three isolates appear to be linked to a single environmental source within the transplant ward.

Mutational differences between EkQ5-EkQ17 and EK6 were mostly non-synonymous in nature, consistent with adaptive evolution. Of the two SNPs separating EkQ17 and EK6, one resulted in a missense (E168K) mutation in a hypothetical protein (Ek00046). Between EkQ5 and EK6, four SNPs resulted in missense mutations, and two caused nonsense mutations in the penicillin-binding protein E (PbpE) and a sugar transporter protein that increased protein length, likely leading to altered or lost protein function (Table 2). In addition, the indel mutation accrued by EkQ5 resulted in a frameshift mutation that elongated hypothetical protein (Ek02802) by nine residues, potentially altering its function.

Another hospital environmental isolate, EK2, was linked to the EkQ5-EkQ17-EK6 clade according to phylogenetic analysis, differing by 38 SNPs and 16 indels (Figure 2). This isolate was collected in 2019 from a sink drain in the infectious disease ward adjacent to the transplant ward where EkQ5, EkQ17 and EK6 were isolated. A more distantly related clinical isolate, EkS2, also clustered within the same clade as the EkQ5-EkQ17-EK6-EK2 isolates but differed from these isolates by 3552 SNPs and 120 indels. Consistent with the phylogenomic findings, EkS2 was not epidemiologically linked to the EkQ5-EkQ17-EK6-EK2 isolates, being isolated from a patient admitted to a different hospital in 2015.

Minimum Inhibitory Concentrations (MIC)

A total of 39 clinically relevant antimicrobials were tested across the 22 clinical *E. anophelis*, *miricola* and *meningoseptica* isolates. Modal MICs were relatively consistent within and between species and predominantly sat on the higher end of the ranges tested (Tables 3 & 4). *Elizabethkingia* does not have a defined clinical breakpoint, therefore species were examined

against the EUCAST “non-species” and CLSI “non-Enterobacteriaceae” PK-PD breakpoints. EUCAST breakpoints suggest Australian strains have the greatest resistance to cephalosporins, carbapenems and penicillins even in combination with β -lactamase inhibitors (amoxicillin-clavulanic acid, piperacillin-tazobactam and ampicillin-sulbactam). Furthermore, the CLSI breakpoints suggest high levels of resistance to amikacin, gentamicin, tobramycin and chloramphenicol. From the MIC values (Tables 3 & 4), only a select few antimicrobials had modal MICs in the lower range, including tetracyclines (doxycycline 2 $\mu\text{g/mL}$ and minocycline 0.5-1 $\mu\text{g/mL}$), fluoroquinolones (ciprofloxacin 0.25 $\mu\text{g/mL}$ and levofloxacin 0.25 $\mu\text{g/mL}$) and trimethoprim-sulfamethoxazole 1 $\mu\text{g/mL}$ (Tables 3 & 4). Only minocycline achieved 100% susceptibility across all *E. anophelis* strains using the CLSI non-Enterobacteriaceae PK-PD breakpoints. Rifampicin and azithromycin do not have corresponding EUCAST or CLSI PK-PD breakpoints; however, their respective modal MICs are also on the lower end of the ranges tested, suggesting the potential for susceptibility. One *E. anophelis* isolate EkQ6 was responsible for the low MICs observed across the antimicrobials tested, remaining susceptible to cephalosporins and carbapenems, in addition to the fluoroquinolones, tetracyclines and trimethoprim-sulfamethoxazole.

In silico antimicrobial resistance (AMR) genes

All 22 clinical *Elizabethkingia* spp. genomes carried all three previously described β -lactamases characteristic of *Elizabethkingia*. The chromosomal extended spectrum β -lactamase *bla*_{CME} encodes cephalosporin and β -lactamase activity, while metallo- β -lactamases *bla*_{BlaB}, and *bla*_{GOB} encode activity against carbapenems and β -lactam/ β -lactamase inhibitor combinations. The metallo- β -lactamase *bla*_{BlaB}, carried a missense mutation of *bla*_{BlaB} ^{Δ T16A} in EkQ6. Except for *E. bruuniana* EkQ11, all Australian *Elizabethkingia* spp. genomes carried

320 the vancomycin resistance protein VanW. Three *E. miricola* and the *E. bruuniana* isolate
 321 carried an AmpC variant with 94-95% sequence similarity to AmpC identified in *E.*
 322 *anophelis* and *E. miricola* genomes (accession numbers CP006576, CP007547 and
 323 CP011059). All isolates carried a conserved AmpG, with three strains exhibiting AmpG^{ΔM1-}
 324 ^{A243} and one strain exhibiting AmpG^{ΔM1-A3} 5' truncations.

Discussion

Elizabethkingia spp. have caused serious nosocomial infections and outbreaks globally yet have received little attention to date. This study aimed to fill knowledge gaps surrounding diversity, origin and transmission events of clinical and environmental *Elizabethkingia* spp. isolates from Australia, a previously unstudied geographic, using comparative genomics. In parallel, we also describe the antimicrobial resistance profiles among Australian clinical *Elizabethkingia* spp. isolates from broth microdilution data against 39 antimicrobials, to further increase our understanding of suitable treatment options.

Elizabethkingia speciation using comparative genomics vs mass spectrometry

The 28 Australian *Elizabethkingia* isolates were identified as *E. anophelis*, *E. meningoseptica*, *E. miricola* and *E. bruuniana*, with *E. anophelis* as the primary infecting species in Australia, similar to recent global reports^{7,22,25}. These isolates, from a previously under-represented geographic area, contribute to ~20% of the diversity seen in the current reference genome database. Despite previous review of identification failing using mass spectroscopy for species other than *E. anophelis* and *E. meningoseptica*⁴, the VITEK[®] MS Knowledge Base v3.2 performed reliably in this study with 96.2% accuracy. *E. bruuniana* was the only *Elizabethkingia* species that could not be accurately identified, instead identified as the sister species *E. miricola*. This could be due to the species not yet being present in the database, or perhaps *E. miricola* and *E. bruuniana* being variations of the same species, as many previous speciation errors were seen in the genus phylogeny (Figure 1). Nevertheless, identification of *E. miricola* should be taken with caution until the database has been upgraded with the capabilities to differentiate between the sister-species.

Australian Elizabethkingia and global relatedness

Our Australian clinical isolates were unique, yet still closely related in comparison to the geographically dispersed reference *Elizabethkingia* spp. genomes (Figures 2-5). The Australian isolates were well dispersed throughout their respective species-specific phylogenies branching with geographically diverse isolates from both clinical and environmental settings. Recently, DNA–DNA hybridization and average nucleotide identity have allowed for the re-classification of *E. miricola* strains ATCC 33958, BM10, and EM798-26 to *E. bruuniana*^{3,25,49}. Further to these corrections, using comparative genomics we suggest the re-classification of *E. miricola* strains 6012926 and CIP111047 to *E. bruuniana*, *E. meningoseptica* strains NCTC10588 and NCTC10586 to *E. anophelis* and lastly, *E. meningoseptica* NCTC11305 to *E. miricola* (Figure 1). Evidence from past studies have described the structure of *E. anophelis* phylogenies to comprise of two and six lineages^{6,50}, in this study we identified six lineages, yet as sampling continues this may expand (Figure 2).

Several *E. anophelis* isolates from this study cluster with the Wisconsin outbreak strains from 2016, the most pathogenic *Elizabethkingia* outbreak to date⁶. Outbreak and hypermutator stains have been characterised by their ICE insertion and truncations at the C terminal in both the MutS and MutY protein sequences respectively⁶. The MutS and MutY protein sequences in our clinical isolates aligned with few non-synonymous amino acid changes and no truncations, therefore it is unlikely the Australian clinical isolates would display the outbreak or hypermutator phenotype, which could be responsible for the increased pathogenesis of the Wisconsin strains. Pathogenicity islands were identified in both Australian and Wisconsin *E.*

anophelis strains, suggesting they may play an important role in the species survival or pathogenesis.

Hospital environmental isolates EK1, 3, 4, 5 formed a clonal cluster and were closely related to two 2012 Singaporean clinical isolates, NUH6 and NUH11. The Australian environmental isolates differed from the Singaporean isolates by 656-867 SNPs and 41-72 indels suggesting shared ancestry.

Potential nosocomial transmission of E. anophelis in a transplant ward

A recent case of hospital acquired *E. anophelis* infection was suggested by the identification of a clonal cluster comprised of clinical and environmental isolates in this study. A pair of Australian *E. anophelis* clinical isolates EkQ5 and EkQ17, collected almost a year apart in 2018 from two patients on the transplant ward were characterised as differing by only eight SNPs and one deletion. Additionally, it was found that the hospital environmental sample collected from a hand washing sink in the same transplant ward in late 2019 only differed to clinical sample EkQ5 by six of the above SNPs and the one deletion. The combination of clinical and environmental genomic data, with such low genetic diversity suggests these strains were transmitted via the common reservoir of the hand-washing sink given the extended time frame between patient infection and environmental collection. Near identical isolates have been described previously within *E. anophelis*, such as environmentally collected OSUVM-1 and 2 isolates⁵¹, hospital outbreak strains NUHP⁵² and Wisconsin CSID⁶ strains, suggesting low genetic variation is not unusual amongst *E. anophelis* infections. The relatedness of sink or toilet environment hospital isolates EK4 and EK5 from the transplant ward, to EK1 and EK3 in the oncology ward suggest that another transmission event may

have also taken place, despite not identifying a related clinical isolate. Previous studies have reported contaminated communal water sources as a reservoir for *Elizabethkingia* spp. infections within hospitals^{1,17}, with hand-washing stations in a paediatric intensive care unit the source of several *Elizabethkingia* spp. infections in Singapore, where staff transmitted the infection after handwashing². Although, direct human-to-human transmission is seen in many other nosocomial infections^{53,54} and vertical transmission has been reported in *E. anophelis*⁵⁵ the role human-to-human transmission has in *Elizabethkingia* infections still remains unclear. However, given the severity of infection, known patient risk factors and the suggested longevity of the bacteria in the environment, the potential for horizontal transmission should not be overlooked.

Minimum Inhibitory Concentrations (MIC) testing

The MIC data generated in this study confirm the Australian clinical *Elizabethkingia* spp. isolates (with the exception of isolate EkQ6), like those in previous studies, are resistant to many antimicrobial classes, including cephalosporins, carbapenems and aminoglycosides (Tables 3 & 4)^{12,23,24,28,56,56}. From the literature, there is very little variation in *E. anophelis* antimicrobial resistance profiles among isolates from America, Southeast Asia and South Korea. For example, approximately 75-100% of *E. anophelis* isolates were reported as resistant to trimethoprim-sulfamethoxazole^{6,23-25,28}, while 75% of Australian strains remained susceptible. Additionally, 88-95% of isolates were susceptible to piperacillin-tazobactam^{6,23,25,28}, while 68-70% of Australian and South Korean²⁴ isolates were resistant. Vancomycin has been suggested as potential therapy for *E. meningoseptica* infections, therefore we screened our *E. anophelis* strains against vancomycin and additional antimicrobials with Gram-positive activity, such as teicoplanin. Despite some advocating for

vancomycin use in *Elizabethkingia* infections^{4,29–31}, our data shows resistance within Australian clinical isolates, as MIC values were on the high end of the range tested and all isolates, with the exception of *E. bruuniana* (EkQ11), carry the *vanW* gene. This is the first set of MIC data for teicoplanin and, with a modal MIC of 32 µg/mL, these strains appear to be resistant. Similar to that of the Wisconsin outbreak strains⁶, Australian *Elizabethkingia* spp. strains may be susceptible to azithromycin, as the modal MIC of 4 µg/mL is on the lower end of the range tested. Although doxycycline is not often tested on *E. anophelis* in the literature, unlike in our study, others have found their strains highly susceptible²⁸. EUCAST breakpoints suggest 6.25% and 43.75% of Australian *E. anophelis* isolates are resistant to levofloxacin and ciprofloxacin respectively. Variability in fluoroquinolone susceptibility has also been observed in the majority of southeast Asian and American strains^{6,23,25,28,31}. Numerous antimicrobials have been tested across *E. anophelis* isolates in previous studies, although susceptibility to multiple antimicrobial classes like that observed in EkQ6, has not been reported previously. Further testing of *E. anophelis* isolates from Australia and abroad would determine if this type of sensitivity is unique to a subset of Australian strains or is present globally.

In Silico Antimicrobial Resistance (AMR) genes

Antimicrobial resistance genes *bla_{BlaB}*, *bla_{GOB}* and *bla_{CME}* were identified within the genomes of all clinical *Elizabethkingia* spp., linking directly to their observed MIC profiles. All isolates with the exception of EkQ6 were resistant to cephalosporins and penicillins (*bla_{CME}*), carbapenems and β-lactam/β-lactamase inhibitor combinations (*bla_{BlaB}*, and *bla_{GOB}*)^{4,57–59}. However, fluoroquinolone resistance varied in our collection, as described above. Previous studies have described resistance being mediated by a single step amino acid substitution

(Ser83Ile or Ser83Arg) in *gyrA*^{23,25,60}, which was not identified in any of the clinical *Elizabethkingia* sp. isolates. The absence of the mutation has also been reported recently for a single isolate in Taiwan²⁸. Previous studies have linked DNA topoisomerase IV to an assistance type role in fluoroquinolone resistance for *Elizabethkingia* spp.^{28,60}, although this was not identified in our clinical isolate collection either.

In addition, clinical *E. anophelis* isolate EkQ6 carried several mutations not commonly described in proteins BlaB and TopA^{25,28,30,61}, yet remained susceptible to cephalosporins, carbapenems, tetracyclines and fluoroquinolones. The substitutions and deletions respectively, may or may not be linked to the susceptibility of this isolate. The observed susceptibility in EkQ6 could have occurred from in-host adaption, evolution in an environment where exposure to antimicrobials is minimal or mutations that have inadvertently resulted in an adaption to a susceptible phenotype. Comparative genomics including more susceptible isolates such as EkQ6 would provide great insight into the intrinsic antimicrobial resistance mechanisms of *Elizabethkingia* species^{30,62,63}.

Potential antimicrobial therapy for Elizabethkingia spp.

As *Elizabethkingia* spp. are predominantly isolated from the bloodstream and possess chromosomally encoded MBL-type carbapenemases, therapy is guided by multiple factors such as patient condition prior to infection, the severity and source of infection, previous exposure to antimicrobials and individualised MIC data. In this study, Australian isolates appear to be susceptible to fluoroquinolones, tetracyclines and trimethoprim-sulfamethoxazole. Only levofloxacin and minocycline demonstrated 100% susceptibility using CLSI PK-PD breakpoints. Fluoroquinolone treatment alone has proven to be successful in *Elizabethkingia* spp. infections⁶⁴, yet some recommend combination therapy⁶⁵ in order to

mitigate high-level fluoroquinolone resistance for those susceptible to single step mutations. From our and other studies, susceptibility is clearly strain dependent. Our findings suggests rifampicin⁶⁶ or azithromycin could also be effective antimicrobials, although this would require further testing. With this in mind and the recent success of newer antimicrobials against MDR Gram-negative bacteria^{67–69}, it would be of value to further test *Elizabethkingia* spp. against newer antimicrobials such as cefiderocol⁷⁰. Although sporadic, *Elizabethkingia* spp. infections have the potential for high mortality rates and nosocomial outbreaks with few treatment options, therefore additional antimicrobial therapies are required and should be investigated further.

Conclusions

This study has characterised the diversity of Australian *Elizabethkingia* spp. using comparative genomics and antimicrobial resistance genotypically and phenotypically. We have revealed significant strain diversity within Australia and have shown that the VITEK[®] MS Knowledge Base v3.2 can accurately identify *E. anophelis*, *E. meningoseptica* and *E. miricola* species, but is yet to correctly identify *E. bruuniana*. Furthermore, genomic exploration has provided insight into the breadth of the intrinsic MDR nature of *Elizabethkingia* spp. and revealed a potential reservoir for infection within a hospital setting where two patients were infected with near identical strains. Antimicrobial resistance data suggests that clinical isolates are susceptible to fluoroquinolones, tetracyclines and trimethoprim-sulfamethoxazole. In particular, minocycline and levofloxacin showed suitable efficacy against *Elizabethkingia* isolates *in vitro*, although further clinical studies are required to define optimal therapy.

499

500 **Acknowledgements**

501 <https://www.ncbi.nlm.nih.gov/bioproject/PRJNA576977>The authors wish to acknowledge the
502 Study Education and Research Committee of Pathology Queensland (LG), University of the
503 Sunshine Coast (DB), Advance Queensland (AQR F13016-17RD2 for DSS; AQIRF0362018
504 for EPP), and the National Health and Medical Research Council (GNT1157530 for PNAH)
505 for funding this study. We would like to express our gratitude to Mater Pathology, Sullivan
506 and Nicolaides Pathology, and Pathology Queensland for their involvement and support in
507 this project. Finally, we would like to thank the infection control nurses at participating
508 hospitals for environmental sampling.

509

510 **Conflicts of interest**

511 Dr. Paterson reports non-financial support from Ecolab Pty Ltd, Whiteley Corporation, and
512 Kimberly-Clark Professional, during the conduct of the study; personal fees from Merck,
513 Shionogi, Achaogen, AstraZeneca, Leo Pharmaceuticals, Bayer, GlaxoSmithKline, Cubist,
514 Venatorx, Accelerate and Pfizer; grants from Shionogi and Merck (MSD), outside the
515 submitted work. Dr. Harris reports grants from Merck (MSD) and Shionogi, personal fees
516 from Pfizer, outside the submitted work. All other authors declare no conflicts of interest.

517

518 Tables and Figures

519 Table 1. *Elizabethkingia* spp. isolates and associated speciation information included in the
520 current study. Strain EkQ11, highlighted in purple represents a species identification error
521 according to the VITEK[®] MS Knowledge Base v3.2.

Isolate ID	Age (y)	Date collected	Collection site	VITEK MS v3.2 ID	Whole Genome ID
EkQ1	1	2017	Sputum	<i>E. miricola</i>	<i>E. miricola</i>
EkQ3	43	2017	Sputum	<i>E. anophelis</i>	<i>E. anophelis</i>
EkQ4	78	2017	Blood	<i>E. meningoseptica</i>	<i>E. meningoseptica</i>
EkQ5	59	2017	Blood	<i>E. anophelis</i>	<i>E. anophelis</i>
EkQ6	17	2018	Bronchoalveolar lavage	<i>E. anophelis</i>	<i>E. anophelis</i>
EkQ7	69	2018	Blood	<i>E. anophelis</i>	<i>E. anophelis</i>
EkQ8	0	2018	Urine	<i>E. anophelis</i>	<i>E. anophelis</i>
EkQ10	34	2018	Sputum	<i>E. miricola</i>	<i>E. miricola</i>
EkQ11	85	2018	Blood	<i>E. miricola</i>	<i>E. bruuniana</i>
EkQ12	53	2018	Blood	<i>E. meningoseptica</i>	<i>E. meningoseptica</i>
EkQ13	1	2011	Sputum	<i>E. miricola</i>	<i>E. miricola</i>
EkQ15	16	2002	Bronchoalveolar lavage	<i>E. anophelis</i>	<i>E. anophelis</i>
EkQ16	82	2017	Blood	<i>E. anophelis</i>	<i>E. anophelis</i>
EkQ17	66	2018	Blood	<i>E. anophelis</i>	<i>E. anophelis</i>
EkM1	Unknown	2018	Unknown	<i>E. anophelis</i>	<i>E. anophelis</i>
EkM2	Unknown	2018	Unknown	<i>E. anophelis</i>	<i>E. anophelis</i>
EkM3	Unknown	2014	Unknown	<i>E. anophelis</i>	<i>E. anophelis</i>
EkS1	80	2013	Blood	<i>E. anophelis</i>	<i>E. anophelis</i>
EkS2	82	2015	Blood	<i>E. anophelis</i>	<i>E. anophelis</i>
EkS3	74	2016	Blood	<i>E. anophelis</i>	<i>E. anophelis</i>
EkS4	73	2012	Blood	<i>E. anophelis</i>	<i>E. anophelis</i>
EkS5	66	2018	Dialysis fluid	<i>E. anophelis</i>	<i>E. anophelis</i>
EK1	N/A	2019	Toilet sink drain, Oncology Ward	<i>E. anophelis</i>	<i>E. anophelis</i>
EK2	N/A	2019	Corridor sink drain, Infectious Disease Ward	<i>E. anophelis</i>	<i>E. anophelis</i>
EK3	N/A	2019	Hand washing drain, Oncology Ward	<i>E. anophelis</i>	<i>E. anophelis</i>
EK4	N/A	2019	Hand wash dink, Transplant Ward	<i>E. anophelis</i>	<i>E. anophelis</i>
EK5	N/A	2019	Toilet handrail, Transplant Ward	<i>E. anophelis</i>	<i>E. anophelis</i>
EK6	N/A	2019	Toilet sink, Transplant Ward	<i>E. anophelis</i>	<i>E. anophelis</i>

522

523

524

525

Table 2. Single nucleotide polymorphism and deletion differences between strains of the clonal cluster of clinical and environmental *Elizabethkingia anophelis* isolates. Clinical isolates EkQ5 (earliest collected and reference strain) and EkQ17 were collected from two different transplant patients, while Ek6 was collected from a shared handwashing sink on the transplant ward. Grey shading shows no differences, green shows similarities between EkQ17 and EK6, while blue shading highlights unique changes. The proteins affected by each mutation and the resulting amino acid changes are also shown.

533

Mutation	EkQ5 2018	EkQ17 2018	EK6 2019	Protein affected	Effect
SNP	G	A	A	Hypothetical Protein	A10T
SNP	G	A	A	Efflux pump membrane transporter (bepE)	S416R
SNP	C	T	T	3-oxoacyl-[acyl-carrier-protein] synthase 2 (fabF)	R303H
SNP	T	C	C	Penicillin binding protein E (pbpE_7)	*762W (+ 279aa)
SNP	A	T	T	Sugar transporter	*133R (+ 133aa)
SNP	C	T	C	Hypothetical Protein	E168K
SNP	C	T	T	Protease (S41 family)	T161I
SNP	G	A	G	B-galactosidase (lacZ_2)	no change
DEL	CT	C	C	Hypothetical Protein	R65E (+ 9aa)

534

35 Table 3. Minimum inhibitory concentration data derived from broth microdilution testing of the 16 Australian *Elizabethkingia anophelis* clinical isolates
36 against 39 clinically relevant antimicrobials. White cells represent the range of concentration tested for each antimicrobial. EUCAST and CLSI breakpoints are
37 shown on the right where available. Blue and yellow cells indicate no breakpoint is currently available for this antimicrobial.

Antimicrobial ^a	<i>E. anophelis</i> isolates with MIC value (µg/mL) n=16																EUCAST Pk-Pd (non-species specific) breakpoints ^e			CLSI non-Enterobacteriaceae breakpoints ^f		
	.015	.03	.06	.12	.25	.5	1	2	4	8	16	32	64	128	256	512	% S	% I	% R	% S	% I	% R
Cephalexin													16									
Cefazolin							1					15					6.25		93.76			
Cefuroxime											16								100		100	
Cefoxitin											2	2	5	7	1	4						
Cefotaxime					1					15							6.25		93.76	6.25	93.75	
Ceftazidime											16											100
Ceftriaxone									16										100		100	
Cefepime					1					2	13						6.25	12.5	81.25	18.75	81.25	
Ceftaroline											16								100			
Ceftolozane/tazobactam ^b								1	5	3	7						6.25	31.25	62.5			
Amikacin											1	8	7							6.25	50	43.75
Gentamicin										3	13										50	50
Tobramycin											16											100
Meropenem	1										15						6.25		93.7	6.25		93.75
Doripenem					1					15												
Etrapanem				1					15									6.25	93.76			
Imipenem						1					15								100	6.25		93.75
Doxycycline							1	8	2	5										68.75	31.25	
Minocycline					1	7	7				1									100		
Tigecycline						2	7	6	1									12.5	87.5			
Ciprofloxacin		1			6	2	3	3	1								6.25	50	43.75	75	25	
Levofloxacin				2	7	4	2	1									56.25	37.5	6.25	100		
Amoxicillin												16							100			
Ampicillin												16							100			
Amoxicillin/clavulanic acid ^c														16					100			

Ampicillin/sulbactam ^d															16					100			
Temocillin															16								
Piperacillin/tazobactam ^b										2	3	1	10							31.25	68.75	31.25	68.75
Vancomycin										1	9	3	3										
Teicoplanin										3	6	7											
Azithromycin									7	5		3	1										
Aztreonam											16									100		100	
Trimethoprim								1	4	6	5												
Trimethoprim/sulfamethoxazole						3	5	4	2	1	1										75		25
Chloramphenicol												1	2	1	10						6.25	12.50	81.25
Colistin										16													
Polymyxin										16													
Rifampicin					7	8			1														

^aConcentration dilutions tested for each antimicrobial are presented in the table within the white boxes, grey boxes indicate concentrations not tested;

^bTazobactam concentration fixed at 4 mg/L; ^cClavulanic acid concentration fixed at 2 mg/L; ^dSulbactam concentration fixed at 4 mg/L; ^ePharmacokinetic-pharmacodynamic (non-species specific) breakpoints applied from EUCAST Clinical Breakpoint Tables (v. 9.0); ^fNon-*Enterobacteriaceae* breakpoints applied from CLSI M100:29 2019. Note: counts for MIC values at the upper and lower range represent number of isolates that are $\geq$ (maximum) or $\leq$ (minimum) that value. See Supplementary File 1 for complete MIC data.

15 Table 4. Minimum inhibitory concentration data derived from broth microdilution testing of the 2 *Elizabethkingia meningoseptica* (blue) and 3 *Elizabethkingia*
16 *miricola* (orange) Australian clinical isolates against 39 clinically relevant antimicrobials. White cells represent the range of concentration tested for each
17 antimicrobial. EUCAST and CLSI breakpoints are shown on the right where available. Blue and yellow cells indicate no breakpoint is currently available for
18 this antimicrobial.

19

Antimicrobial ^a	<i>E. miricola</i> (orange) n=3 and <i>E. meningoseptica</i> (blue) n=2 with MIC value (µg/mL)																EUCAST Pk-Pd (non-species specific) breakpoints ^e			CLSI non-Enterobacteriaceae breakpoints ^f		
	.015	.03	.06	.12	.25	.5	1	2	4	8	16	32	64	128	256	512	% S	% I	% R	% S	% I	% R
Cephalexin													3 2									
Cefazolin												3 2							100			
Cefuroxime											3 2								100		100	
Cefoxitin													1	1 1		2						
Cefotaxime										3 2									100		100	
Ceftazidime											3 2								100			100
Ceftriaxone									3 2										100		100	
Cefepime											3 2								100			100
Ceftaroline											3 2								100			
Ceftolozane/tazobactam ^b											3 2								100			
Amikacin											1	2 1	1							33.3	66.6 50	50
Gentamicin										1 1	2 1									50 50		66.6 50
Tobramycin											3 2											100
Meropenem											3 2								100			100
Doripenem										3 2												
Etrapanem									3 2										100			
Imipenem											3 2								100			100
Doxycycline								1 2	1	1										66.6 100	33.3	
Minocycline					1	1 2	1													100		
Tigecycline					1	1	1 1			1									100			
Ciprofloxacin				1	1	3											100	100		100		
Levofloxacin					2		3										100		100	100		
Amoxicillin											3 2								100			
Ampicillin											3 2								100			
Amoxicillin/clavulanic acid ^c													3 2						100			

Ampicillin/sulbactam ^d														3 2					100			
Temocillin													3 2									
Piperacillin/tazobactam ^b											1	3 1							100		100	
Vancomycin										1	1 2	1										
Teicoplanin											1	2 2										
Azithromycin									1	1	1	1 1										
Aztreonam											3 2								100		100	
Trimethoprim									1 1	1	2											
Trimethoprim/sulfamethoxazole						1		1 1	2											33.3 50		66.6
Chloramphenicol											2	3								100	100	
Colistin										3 2												
Polymyxin										3 2												
Rifampicin					1	2 1					1											

^aConcentration dilutions tested for each antimicrobial are presented in the table within the white boxes, grey boxes indicate concentrations not tested; ^bTazobactam concentration fixed at 4 mg/L; ^cClavulanic acid concentration fixed at 2 mg/L; ^dSulbactam concentration fixed at 4 mg/L; ^ePharmacokinetic-pharmacodynamic (non-species specific) breakpoints applied from EUCAST Clinical Breakpoint Tables (v. 9.0); ^fNon-*Enterobacteriaceae* breakpoints applied from CLSI M100:29 2019. Note: counts for MIC values at the upper and lower range represent number of isolates that are $\geq$ (maximum) or $\leq$ (minimum) that value. See Supplementary File 1 for complete MIC data.

Figure 1. Global phylogenomic analysis of *Elizabethkingia* spp. genomes. Maximum parsimony midpoint-rooted phylogeny. Branches returning bootstrap support <0.8 are labelled. This phylogeny was reconstructed using 127,236 biallelic, orthologous single-nucleotide polymorphisms identified among the 128 *Elizabethkingia* genomes. Consistency index = 0.4066.

Figure 2. *Elizabethkingia anophelis* species specific phylogenomic analysis. Maximum parsimony midpoint-rooted phylogeny was reconstructed using 121,827 biallelic, orthologous single-nucleotide polymorphisms identified among the 71 *Elizabethkingia anophelis* genomes. Correctly speciated *Elizabethkingia anophelis* genomes are coloured green, incorrectly speciated *Elizabethkingia meningoseptica* genomes are coloured blue and

567 new *Elizabethkingia anophelis* genomes generated in this study are coloured black. Bootstrap
568 support <0.8 are labelled. Consistency index = 0.3110.

569

570

571

572

573

574

575

576

577

Figure 3. *Elizabethkingia miricola* species specific phylogenomic analysis. Maximum parsimony midpoint-rooted phylogeny was reconstructed using 135,087 biallelic, orthologous single-nucleotide polymorphisms identified among the 18 genomes. Correctly speciated *E. miricola* strains are coloured orange, incorrectly speciated *Elizabethkingia meningoseptica* coloured blue and *Elizabethkingia anophelis* genomes generated in this study coloured black. Bootstrap support <0.80 is shown. Consistency index = 0.7404.

Figure 4. *Elizabethkingia meningoseptica* species specific phylogenomic analysis. Maximum parsimony midpoint-rooted phylogeny was reconstructed using 61,500 biallelic, orthologous single-nucleotide polymorphisms identified among the 22 genomes. Reference *Elizabethkingia meningoseptica* strains are coloured blue with strains generated in this study coloured black. Bootstrap support is 100 for all branches. Consistency index = 0.6895.

Figure 5. *Elizabethkingia bruniana* species specific phylogenomic analysis. Maximum parsimony midpoint-rooted phylogeny was reconstructed using 82,680 biallelic, orthologous single-nucleotide polymorphisms identified among the 10 genomes. Correctly speciated *Elizabethkingia bruniana* strains are coloured red, incorrectly speciated *Elizabethkingia miricola* strains are coloured orange and genomes generated in this study are coloured black. Bootstrap support <0.8 is shown. Consistency index = 0.8729.

617 **Supplementary Material**

618 Table S1. Metadata and ID of the 100 *Elizabethkingia* NCBI and SRA reference genomes
619 used in this study.

620 Table S2: SPAdes and prokka genome assembly and annotation statistics of Australian
621 *Elizabethkingia* clinical isolates analysed in this study.

622

References

1. Moore, L. S. P. *et al.* Waterborne *Elizabethkingia meningoseptica* in Adult Critical Care. *Emerg. Infect. Dis.* **22**, 9–17 (2016).
2. Yung, C.-F. *et al.* *Elizabethkingia anophelis* and Association with Tap Water and Handwashing, Singapore. *Emerg. Infect. Dis.* **24**, 1730–1733 (2018).
3. Nicholson, A. C. *et al.* Revisiting the taxonomy of the genus *Elizabethkingia* using whole-genome sequencing, optical mapping, and MALDI-TOF, along with proposal of three novel *Elizabethkingia* species: *Elizabethkingia bruuniana* sp. nov., *Elizabethkingia ursingii* sp. nov., and *Elizabethkingia occulta* sp. nov. *Antonie Van Leeuwenhoek* **111**, 55–72 (2018).
4. Lin, J.-N., Lai, C.-H., Yang, C.-H. & Huang, Y.-H. *Elizabethkingia* Infections in Humans: From Genomics to Clinics. *Microorganisms* **7**, 295 (2019).
5. Nicholson, A. C., Humrighouse, B. W., Graziano, J. C., Emery, B. & McQuiston, J. R. Draft Genome Sequences of Strains Representing Each of the *Elizabethkingia* Genomespecies Previously Determined by DNA-DNA Hybridization. *Genome Announc.* **2**.
6. Perrin, A. *et al.* Evolutionary dynamics and genomic features of the *Elizabethkingia anophelis* 2015 to 2016 Wisconsin outbreak strain. *Nat. Commun.* **8**, 15483 (2017).
7. Chew, K. L., Cheng, B., Lin, R. T. P. & Teo, J. W. P. *Elizabethkingia anophelis* Is the Dominant *Elizabethkingia* Species Found in Blood Cultures in Singapore. *J. Clin. Microbiol.* **56**, (2018).
8. Jean, S. S., Lee, W. S., Chen, F. L., Ou, T. Y. & Hsueh, P. R. *Elizabethkingia meningoseptica*: an important emerging pathogen causing healthcare-associated infections. *J. Hosp. Infect.* **86**, 244–249 (2014).

- 647 9. Frank, T. *et al.* First case of *Elizabethkingia anophelis* meningitis in the Central African
648 Republic. *Lancet Lond. Engl.* **381**, 1876 (2013).
- 649 10. Issack, M. I. & Neetoo, Y. An outbreak of *Elizabethkingia meningoseptica* neonatal
650 meningitis in Mauritius. *J. Infect. Dev. Ctries.* **5**, 834–839 (2011).
- 651 11. Teo, J. *et al.* First case of *E. anophelis* outbreak in an intensive-care unit. *The Lancet* **382**,
652 855–856 (2013).
- 653 12. Hsu, M.-S. *et al.* Clinical features, antimicrobial susceptibilities, and outcomes of
654 *Elizabethkingia meningoseptica* (*Chryseobacterium meningosepticum*) bacteremia at a
655 medical center in Taiwan, 1999–2006. *Eur. J. Clin. Microbiol. Infect. Dis.* **30**, 1271–1278
656 (2011).
- 657 13. Choi, M. H. *et al.* Risk Factors for *Elizabethkingia* Acquisition and Clinical
658 Characteristics of Patients, South Korea. *Emerg. Infect. Dis.* **25**, 42–51 (2019).
- 659 14. Janda, J. M. & Lopez, D. L. Mini review: New pathogen profiles: *Elizabethkingia*
660 *anophelis*. *Diagn. Microbiol. Infect. Dis.* **88**, 201–205 (2017).
- 661 15. Weaver, K. N. *et al.* Acute emergence of *Elizabethkingia meningoseptica* infection
662 among mechanically ventilated patients in a long-term acute care facility. *Infect. Control*
663 *Hosp. Epidemiol.* **31**, 54–58 (2010).
- 664 16. Chawla, K., Gopinathan, A., Varma, M. & Mukhopadhyay, C. *Elizabethkingia*
665 *Meningoseptica* Outbreak in Intensive Care Unit. *J. Glob. Infect. Dis.* **7**, 43–44 (2015).
- 666 17. Kyritsi, M. A., Mouchtouri, V. A., Pournaras, S. & Hadjichristodoulou, C. First reported
667 isolation of an emerging opportunistic pathogen (*Elizabethkingia anophelis*) from
668 hospital water systems in Greece. *J. Water Health* **16**, 164–170 (2018).
- 669 18. Doijad, S., Ghosh, H., Glaeser, S., Kämpfer, P. & Chakraborty, T. Taxonomic
670 reassessment of the genus *Elizabethkingia* using whole-genome sequencing:
671 *Elizabethkingia endophytica* Kämpfer et al. 2015 is a later subjective synonym of

- 672 *Elizabethkingia anophelis* Kämpfer et al. 2011. *Int. J. Syst. Evol. Microbiol.* **66**, 4555–
673 4559 (2016).
- 674 19. Li, Y. *et al.* *Chryseobacterium miricola* sp. nov., A Novel Species Isolated from
675 Condensation Water of Space Station Mir. *Syst. Appl. Microbiol.* **26**, 523–528 (2003).
- 676 20. Kämpfer, P. *et al.* *Elizabethkingia anophelis* sp. nov., isolated from the midgut of the
677 mosquito *Anopheles gambiae*. *Int. J. Syst. Evol. Microbiol.* **61**, 2670–2675 (2011).
- 678 21. Jorgensen, J. H. & P. Faller, M. A. Introduction to the 11th Edition of the Manual of
679 Clinical Microbiology. *Man. Clin. Microbiol. Elev. Ed.* 3–4 (2015)
680 doi:10.1128/9781555817381.ch1.
- 681 22. Lau, S. K. P. *et al.* *Elizabethkingia anophelis* bacteremia is associated with clinically
682 significant infections and high mortality. *Sci. Rep.* **6**, (2016).
- 683 23. Lin, J.-N., Lai, C.-H., Yang, C.-H., Huang, Y.-H. & Lin, H.-H. Clinical manifestations,
684 molecular characteristics, antimicrobial susceptibility patterns and contributions of target
685 gene mutation to fluoroquinolone resistance in *Elizabethkingia anophelis*. *J. Antimicrob.*
686 *Chemother.* **73**, 2497–2502 (2018).
- 687 24. Han, M.-S. *et al.* Relative Prevalence and Antimicrobial Susceptibility of Clinical
688 Isolates of *Elizabethkingia* Species Based on 16S rRNA Gene Sequencing. *J. Clin.*
689 *Microbiol.* **55**, 274–280 (2017).
- 690 25. Lin, J.-N., Lai, C.-H., Yang, C.-H. & Huang, Y.-H. Comparison of Clinical
691 Manifestations, Antimicrobial Susceptibility Patterns, and Mutations of Fluoroquinolone
692 Target Genes between *Elizabethkingia meningoseptica* and *Elizabethkingia anophelis*
693 Isolated in Taiwan. *J. Clin. Med.* **7**, (2018).
- 694 26. Lin, Y.-T. *et al.* Clinical and microbiological analysis of *Elizabethkingia meningoseptica*
695 bacteremia in adult patients in Taiwan. *Scand. J. Infect. Dis.* **41**, 628–634 (2009).

- 696 27. Tai, I.-C. *et al.* Outbreak of *Elizabethkingia meningoseptica* sepsis with meningitis in a
697 well-baby nursery. *J. Hosp. Infect.* **96**, 168–171 (2017).
- 698 28. Jian, M.-J. *et al.* Fluoroquinolone resistance in carbapenem-resistant *Elizabethkingia*
699 *anophelis*: phenotypic and genotypic characteristics of clinical isolates with
700 topoisomerase mutations and comparative genomic analysis. *8* (2019).
- 701 29. Jean, S.-S., Hsieh, T.-C., Ning, Y.-Z. & Hsueh, P.-R. Role of vancomycin in the
702 treatment of bacteraemia and meningitis caused by *Elizabethkingia meningoseptica*. *Int.*
703 *J. Antimicrob. Agents* **50**, 507–511 (2017).
- 704 30. Chang, T.-Y., Chen, H.-Y., Chou, Y.-C., Cheng, Y.-H. & Sun, J.-R. In vitro activities of
705 imipenem, vancomycin, and rifampicin against clinical *Elizabethkingia* species producing
706 BlaB and GOB metallo-beta-lactamases. *Eur. J. Clin. Microbiol. Infect. Dis.* (2019)
707 doi:10.1007/s10096-019-03639-3.
- 708 31. Han, M.-S. *et al.* Relative Prevalence and Antimicrobial Susceptibility of Clinical
709 Isolates of *Elizabethkingia* Species Based on 16S rRNA Gene Sequencing. *J. Clin.*
710 *Microbiol.* **55**, 274–280 (2017).
- 711 32. Bolger, A. M., Lohse, M., & Usadel, B. Trimmomatic: A flexible trimmer for Illumina
712 Sequence Data. *Bioinforma. Btu170* (2014).
- 713 33. Ewels, P., Magnusson, M., Lundin, S. & Käller, M. MultiQC: summarize analysis results
714 for multiple tools and samples in a single report. *Bioinformatics* **32**, 3047–3048 (2016).
- 715 34. H. Li. Seqtk: a fast and lightweight tool for processing FASTA or FASTQ sequences.
716 (2013).
- 717 35. Huang, W., Li, L., Myers, J. R. & Marth, G. T. ART: a next-generation sequencing read
718 simulator. *Bioinformatics* **28**, 593–594 (2012).

- 719 36. Nurk, S. *et al.* Assembling Genomes and Mini-metagenomes from Highly Chimeric
720 Reads. in *Research in Computational Molecular Biology* (eds. Deng, M., Jiang, R., Sun,
721 F. & Zhang, X.) 158–170 (Springer Berlin Heidelberg, 2013).
- 722 37. Seemann, T. Prokka: rapid prokaryotic genome annotation. *Bioinforma. Oxf. Engl.* **30**,
723 2068–2069 (2014).
- 724 38. Sarovich, D. S. & Price, E. P. SPANDx: a genomics pipeline for comparative analysis of
725 large haploid whole genome re-sequencing datasets. *BMC Res. Notes* **7**, 618 (2014).
- 726 39. Swofford, D. L. PAUP* ver 4.0. b10. *Phylogenetic Anal. Using Parsimony Methods*
727 *Sunderland MA Sinauer Assoc. Sunderland* (2003).
- 728 40. Using Tablet for visual exploration of second-generation sequencing data | Briefings in
729 Bioinformatics | Oxford Academic.
730 <https://academic.oup.com/bib/article/14/2/193/208254>.
- 731 41. Kearse, M. *et al.* Geneious Basic: an integrated and extendable desktop software platform
732 for the organization and analysis of sequence data. *Bioinforma. Oxf. Engl.* **28**, 1647–1649
733 (2012).
- 734 42. Aziz, R. K. *et al.* The RAST Server: rapid annotations using subsystems technology.
735 *BMC Genomics* **9**, 75 (2008).
- 736 43. Kahlmeter, G. *et al.* European Committee on Antimicrobial Susceptibility Testing
737 (EUCAST) Technical Notes on antimicrobial susceptibility testing. *Clin. Microbiol.*
738 *Infect.* **12**, 501–503 (2006).
- 739 44. Clinical and Laboratory Standards Institute. CLSI guideline M45. Methods for
740 Antimicrobial Dilution and Disk Susceptibility Testing of Infrequently Isolated or
741 Fastidious Bacteria. 3rd ed, Wayne, PA: Clinical and Laboratory Standards Institute;
742 2016.

- 743 45. Jorgensen, J. H., Hindler, J. F., Reller, L. B. & Weinstein, M. P. New Consensus
744 Guidelines from the Clinical and Laboratory Standards Institute for Antimicrobial
745 Susceptibility Testing of Infrequently Isolated or Fastidious Bacteria. *Clin. Infect. Dis.*
746 **44**, 280–286 (2007).
- 747 46. Clinical and Laboratory Standards Institute. 2015. M7-A10: methods for dilution
748 antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard,
749 10th ed. Clinical and Laboratory Standards Institute, Wayne, PA.
- 750 47. Brettin, T. *et al.* RASTtk: a modular and extensible implementation of the RAST
751 algorithm for building custom annotation pipelines and annotating batches of genomes.
752 *Sci. Rep.* **5**, 8365 (2015).
- 753 48. Overbeek, R. *et al.* The SEED and the Rapid Annotation of microbial genomes using
754 Subsystems Technology (RAST). *Nucleic Acids Res.* **42**, D206-214 (2014).
- 755 49. Lin, J.-N., Lai, C.-H., Yang, C.-H., Huang, Y.-H. & Lin, H.-H. Genomic features,
756 phylogenetic relationships, and comparative genomics of *Elizabethkingia anophelis* strain
757 EM361-97 isolated in Taiwan. *Sci. Rep.* **7**, (2017).
- 758 50. Breurec, S. *et al.* Genomic epidemiology and global diversity of the emerging bacterial
759 pathogen *Elizabethkingia anophelis*. *Sci. Rep.* **6**, (2016).
- 760 51. Johnson, W. L. *et al.* The draft genomes of *Elizabethkingia anophelis* of equine origin are
761 genetically similar to three isolates from human clinical specimens. *PLOS ONE* **13**,
762 e0200731 (2018).
- 763 52. Teo, J. *et al.* Comparative Genomic Analysis of Malaria Mosquito Vector-Associated
764 Novel Pathogen *Elizabethkingia anophelis*. *Genome Biol. Evol.* **6**, 1158–1165 (2014).
- 765 53. Tagoe, D. N. A., Baidoo, S., Dadzie, I., Tengey, D. & Agede, C. Potential Sources of
766 Transmission of Hospital Acquired Infections in the Volta Regional Hospital in Ghana.
767 *Ghana Med. J.* **45**, 22–26 (2011).

54. Khan, H. A., Baig, F. K. & Mehboob, R. Nosocomial infections: Epidemiology, prevention, control and surveillance. *Asian Pac. J. Trop. Biomed.* **7**, 478–482 (2017).
55. Lau, S. K. P. *et al.* Evidence for *Elizabethkingia anophelis* transmission from mother to infant, Hong Kong. *Emerg. Infect. Dis.* **21**, 232–241 (2015).
56. Lin, J.-N., Lai, C.-H., Yang, C.-H., Huang, Y.-H. & Lin, H.-H. Genomic Features, Comparative Genomics, and Antimicrobial Susceptibility Patterns of *Elizabethkingia bruuniana*. *Sci. Rep.* **9**, 2267 (2019).
57. Bellais, S., Poirel, L., Naas, T., Girlich, D. & Nordmann, P. Genetic-biochemical analysis and distribution of the Ambler class A beta-lactamase CME-2, responsible for extended-spectrum cephalosporin resistance in *Chryseobacterium* (Flavobacterium) *meningosepticum*. *Antimicrob. Agents Chemother.* **44**, 1–9 (2000).
58. Rossolini, G. M. *et al.* Cloning of a *Chryseobacterium* (Flavobacterium) *meningosepticum* chromosomal gene (blaA(CME)) encoding an extended-spectrum class A beta-lactamase related to the Bacteroides cephalosporinases and the VEB-1 and PER beta-lactamases. *Antimicrob. Agents Chemother.* **43**, 2193–2199 (1999).
59. Colapietro, M. *et al.* BlaB-15, a new BlaB metallo-beta-lactamase variant found in an *Elizabethkingia miricola* clinical isolate. *Diagn. Microbiol. Infect. Dis.* **85**, 195–197 (2016).
60. Jian, M.-J., Cheng, Y.-H., Perng, C.-L. & Shang, H.-S. Molecular typing and profiling of topoisomerase mutations causing resistance to ciprofloxacin and levofloxacin in *Elizabethkingia* species. *PeerJ* **6**, (2018).
61. Wang, M. *et al.* The antibiotic resistance and pathogenicity of a multidrug-resistant *Elizabethkingia anophelis* isolate. *MicrobiologyOpen* **0**, e804.
62. Opota, O. *et al.* Genome of the carbapenemase-producing clinical isolate *Elizabethkingia miricola* EM_CHUV and comparative genomics with *Elizabethkingia meningoseptica*

- 793 and *Elizabethkingia anophelis*: evidence for intrinsic multidrug resistance trait of
- 794 emerging pathogens. *Int. J. Antimicrob. Agents* **49**, 93–97 (2017).
- 795 63. Balm, M. N. *et al.* Bad design, bad practices, bad bugs: frustrations in controlling an
- 796 outbreak of *Elizabethkingia meningoseptica* in intensive care units. *J Hosp Infect* **85**,
- 797 134–40 (2013).
- 798 64. Huang, Y.-C., Lin, Y.-T. & Wang, F.-D. Comparison of the therapeutic efficacy of
- 799 fluoroquinolone and non-fluoroquinolone treatment in patients with *Elizabethkingia*
- 800 *meningoseptica* bacteraemia. *Int. J. Antimicrob. Agents* **51**, 47–51 (2018).
- 801 65. Chan, J. C. *et al.* Invasive paediatric *Elizabethkingia meningoseptica* infections are best
- 802 treated with a combination of piperacillin/tazobactam and trimethoprim/sulfamethoxazole
- 803 or fluoroquinolone. *J. Med. Microbiol.* **68**, 1167–1172 (2019).
- 804 66. Bassetti, M., Peghin, M., Vena, A. & Giacobbe, D. R. Treatment of Infections Due to
- 805 MDR Gram-Negative Bacteria. *Front. Med.* **6**, (2019).
- 806 67. Hackel, M. A. *et al.* In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol,
- 807 against Carbapenem-Nonsusceptible and Multidrug-Resistant Isolates of Gram-Negative
- 808 Bacilli Collected Worldwide in 2014 to 2016. *Antimicrob. Agents Chemother.* **62**, (2018).
- 809 68. Haidar, G. *et al.* Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant
- 810 *Pseudomonas aeruginosa* Infections: Clinical Effectiveness and Evolution of Resistance.
- 811 *Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am.* **65**, 110–120 (2017).
- 812 69. Shields, R. K. *et al.* Verification of Ceftazidime-Avibactam and Ceftolozane-Tazobactam
- 813 Susceptibility Testing Methods against Carbapenem-Resistant Enterobacteriaceae and
- 814 *Pseudomonas aeruginosa*. *J. Clin. Microbiol.* **56**, (2018).
- 815 70. Zhanel, G. G. *et al.* Cefiderocol: A Siderophore Cephalosporin with Activity Against
- 816 Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli. *Drugs* **79**, 271–
- 817 289 (2019).